According to filings with the U.S. Securities and Exchange Commission, Interpace Biosciences is raising up to $47,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Thomas Burnell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Interpace Biosciences
Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace Pharma Solutions provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries and advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

To learn more about Interpace Biosciences, visit http://interpace.com/
Interpace Biosciences Linkedin Page: https://www.linkedin.com/company/idxgbiosciences/

Contact:
Thomas Burnell, President and Chief Executive Officer
855-776-6419
https://www.linkedin.com/in/tom-burnell-020648118/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.